PTC Therapeutics (PTCT) Stock Forecast & Price Target

$31.54

-0.06 (-0.19%)

(As of 09/6/2024 ET)

PTC Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 16 Analyst Ratings

Based on 16 Wall Street analysts who have issued ratings for PTC Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 3 have given a sell rating, 6 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for PTCT.

Consensus Price Target

$37.13
17.73% Upside

High Forecast	$64.00
Average Forecast	$37.13
Low Forecast	$25.00

According to the 16 analysts' twelve-month price targets for PTC Therapeutics, the average price target is $37.13. The highest price target for PTCT is $64.00, while the lowest price target for PTCT is $25.00. The average price target represents a forecasted upside of 17.73% from the current price of $31.54.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	5 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$37.13	$35.23	$35.67	$52.80
Forecasted Upside	17.73% Upside	12.42% Upside	13.58% Upside	18.06% Upside

Get PTC Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

Ad Golden Crest

Biden’s Capital Gains Tax to Devastate Savings!

Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.

>> Get Your FREE Wealth Protection Guide <<

PTCT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PTCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

PTC Therapeutics Stock vs. The Competition

Type	PTC Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.31	2.77	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	17.73% Upside	1,206.55% Upside	11.36% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/4/2024	Baird R W 0 of 5 stars	J. Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2024	Robert W. Baird 2 of 5 stars		Initiated Coverage	Outperform	$44.00	+31.70%
8/26/2024	UBS Group 4 of 5 stars	E. Merle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$47.00	+33.83%
8/21/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$64.00 ➝ $64.00	+86.21%
8/9/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $31.00	-4.47%
7/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $32.00	-2.71%
Get the Latest News and Ratings for PTCT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
6/21/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underperform ➝ Underperform	$25.00 ➝ $32.00	-3.88%
6/20/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$53.00 ➝ $53.00	+60.80%
5/28/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$18.00 ➝ $32.00	-14.16%
5/21/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$18.00 ➝ $26.00	-33.30%
5/20/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$35.00 ➝ $46.00	+15.69%
5/20/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
3/1/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$22.00 ➝ $28.00	-7.32%
3/1/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform ➝ Market Perform	$32.00 ➝ $30.00	+6.42%
12/8/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$37.00	+40.79%
10/5/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$45.00 ➝ $25.00	+12.61%
9/18/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Schwartz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$44.00 ➝ $30.00	+18.81%
7/20/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$50.00	+24.94%
5/18/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
3/22/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/17/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$48.00	-0.21%
11/1/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$44.00	+16.62%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:24 PM ET.

PTCT Forecast - Frequently Asked Questions

What is PTC Therapeutics' forecast for 2024?: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for PTC Therapeutics is $37.13, with a high forecast of $64.00 and a low forecast of $25.00.
Should I buy or sell PTC Therapeutics stock right now?: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 sell ratings, 6 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
Does PTC Therapeutics's stock price have much upside?: According to analysts, PTC Therapeutics's stock has a predicted upside of 14.56% based on their 12-month stock forecasts.
Has PTC Therapeutics been upgraded by Wall Street analysts recently?: Over the previous 90 days, PTC Therapeutics's stock had 1 upgrade by analysts.
What analysts cover PTC Therapeutics?: PTC Therapeutics has been rated by research analysts at Baird R W, Bank of America, Barclays, Cantor Fitzgerald, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, and UBS Group in the past 90 days.
Do Wall Street analysts like PTC Therapeutics more than its competitors?: Analysts like PTC Therapeutics less than other "medical" companies. The consensus rating for PTC Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PTCT compares to other companies.